CHARAH SOLUTIONS INC (CHRA)

US15957P3038 - Common Stock

2.17  +0.08 (+3.83%)

Fundamental Rating

1

CHRA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 85 industry peers in the Commercial Services & Supplies industry. CHRA may be in some trouble as it scores bad on both profitability and health. CHRA does not seem to be growing, but still is valued expensively.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CHRA has reported negative net income.
CHRA had a negative operating cash flow in the past year.
In the past 5 years CHRA reported 4 times negative net income.
In multiple years CHRA reported negative operating cash flow during the last 5 years.

1.2 Ratios

CHRA has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With a Gross Margin value of 1.79%, CHRA is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
CHRA's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for CHRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 1.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24.11%
GM growth 5Y-17.64%

More info and screens

2

2. Health

2.1 Basic Checks

CHRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CHRA has been reduced compared to 1 year ago.
Compared to 1 year ago, CHRA has an improved debt to assets ratio.

2.2 Solvency

CHRA has an Altman-Z score of 0.08. This is a bad value and indicates that CHRA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 0.08, CHRA is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
A Debt/Equity ratio of 7.56 is on the high side and indicates that CHRA has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 7.56, CHRA is doing worse than 91.25% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 7.56
Debt/FCF N/A
Altman-Z 0.08
ROIC/WACCN/A
WACC6.34%

2.3 Liquidity

CHRA has a Current Ratio of 1.14. This is a normal value and indicates that CHRA is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.14, CHRA is doing worse than 61.25% of the companies in the same industry.
CHRA has a Quick Ratio of 1.09. This is a normal value and indicates that CHRA is financially healthy and should not expect problems in meeting its short term obligations.
CHRA's Quick ratio of 1.09 is in line compared to the rest of the industry. CHRA outperforms 48.75% of its industry peers.
Industry RankSector Rank
Current Ratio 1.14
Quick Ratio 1.09

More info and screens

3

3. Growth

3.1 Past

CHRA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -260.00%.
The Revenue has grown by 146.66% in the past year. This is a very strong growth!
Measured over the past years, CHRA shows a small growth in Revenue. The Revenue has been growing by 2.04% on average per year.
EPS 1Y (TTM)-260%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-387.5%
Revenue 1Y (TTM)146.66%
Revenue growth 3Y-9.9%
Revenue growth 5Y2.04%
Revenue growth Q2Q-3.11%

3.2 Future

The Earnings Per Share is expected to decrease by -347.79% on average over the next years. This is quite bad
Based on estimates for the next years, CHRA will show a small growth in Revenue. The Revenue will grow by 7.09% on average per year.
EPS Next Y-436.41%
EPS Next 2Y-91.3%
EPS Next 3Y-347.79%
EPS Next 5YN/A
Revenue Next Year8.8%
Revenue Next 2Y7.2%
Revenue Next 3Y6.72%
Revenue Next 5Y7.09%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CHRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CHRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A cheap valuation may be justified as CHRA's earnings are expected to decrease with -347.79% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-91.3%
EPS Next 3Y-347.79%

More info and screens

2

5. Dividend

5.1 Amount

CHRA has a Yearly Dividend Yield of 1.26%. Purely for dividend investing, there may be better candidates out there.
In the last 3 months the price of CHRA has falen by -70.95%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
Compared to an average industry Dividend Yield of 2.35, CHRA pays a bit more dividend than its industry peers.
With a Dividend Yield of 1.26, CHRA pays less dividend than the S&P500 average, which is at 2.40.
Industry RankSector Rank
Dividend Yield 1.26%

5.2 History

CHRA does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

DP0%
EPS Next 2Y-91.3%
EPS Next 3Y-347.79%

More info and screens

CHARAH SOLUTIONS INC

NYSE:CHRA (4/3/2023, 7:20:29 PM)

2.17

+0.08 (+3.83%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCommercial & Professional Services
GICS IndustryCommercial Services & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap7.33M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield 1.26%
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 1.79%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.86
Health
Industry RankSector Rank
Debt/Equity 7.56
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.14
Quick Ratio 1.09
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-260%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-436.41%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)146.66%
Revenue growth 3Y-9.9%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y